| scholarly article | Q13442814 |
| P50 | author | Peter Lichter | Q2076661 |
| Jacqueline Barrientos | Q42815591 | ||
| Stephan Stilgenbauer | Q47158807 | ||
| Samantha M Jaglowski | Q48356463 | ||
| John C. Byrd | Q66429603 | ||
| Jennifer A Woyach | Q90156409 | ||
| Kristie A Blum | Q90691651 | ||
| Danelle F James | Q92176351 | ||
| Amy S Ruppert | Q114341048 | ||
| Gerard Lozanski | Q114341067 | ||
| Arletta Lozanski | Q117271317 | ||
| P2093 | author name string | Jenny Zhang | |
| Hatice Gulcin Ozer | |||
| Marc Zapatka | |||
| Richard R Furman | |||
| Ling Xue | |||
| Betty Y Chang | |||
| Joseph J Buggy | |||
| Sandeep S Dave | |||
| Amy J Johnson | |||
| Ayse Selen Yilmaz | |||
| Matthias Versele | |||
| Ta-Ming Liu | |||
| Susanne M Steggerda | |||
| Daniel Hsieh-Hsin Li | |||
| P2860 | cites work | Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy | Q37655012 |
| BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations | Q39991847 | ||
| Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain | Q40390558 | ||
| Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation | Q46522701 | ||
| Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression. | Q53610680 | ||
| Survival of leukemic B cells promoted by engagement of the antigen receptor | Q77136413 | ||
| Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors | Q81039035 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 | ||
| Fast and accurate short read alignment with Burrows-Wheeler transform | Q24653853 | ||
| Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain | Q24794765 | ||
| Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1 | Q27678436 | ||
| EGFR mutation and resistance of non-small-cell lung cancer to gefitinib | Q27824829 | ||
| Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia | Q27851767 | ||
| The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data | Q27860742 | ||
| Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia | Q29614659 | ||
| A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3 | Q29614852 | ||
| Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification | Q29618788 | ||
| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 | ||
| Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia | Q34016866 | ||
| Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. | Q34026194 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo | Q34029869 | ||
| SF3B1 and other novel cancer genes in chronic lymphocytic leukemia | Q34093678 | ||
| Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia | Q34183674 | ||
| Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples | Q34327021 | ||
| B cell antigen receptor signaling 101. | Q35818846 | ||
| Ibrutinib resistance in chronic lymphocytic leukemia | Q35881570 | ||
| The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib | Q35925610 | ||
| A hypermorphic missense mutation in PLCG2, encoding phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with immunodeficiency | Q36358469 | ||
| BTKbase: the mutation database for X-linked agammaglobulinemia. | Q36592292 | ||
| Evolution and impact of subclonal mutations in chronic lymphocytic leukemia | Q36619124 | ||
| Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes | Q37226729 | ||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ibrutinib | Q5984881 |
| P304 | page(s) | 2286-94 | |
| P577 | publication date | 2014-06-12 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib | |
| P478 | volume | 370 |
| Q64764750 | Q64764750 |
| Q92022521 | A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines |
| Q54979456 | A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. |
| Q54112410 | A Case Report of Nongerminal Center B-Cell Type Diffuse Large B-Cell Lymphoma Treated to Complete Response with Rituximab and Ibrutinib. |
| Q53682041 | A Convergence-Based Framework for Cancer Drug Resistance. |
| Q35794593 | A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia |
| Q64443593 | A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity |
| Q40736899 | A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL. |
| Q41827341 | A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma |
| Q91735722 | A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia |
| Q36413780 | A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2. |
| Q63364698 | AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival |
| Q58093956 | Aberrant Activation of NF-κB Signalling in Aggressive Lymphoid Malignancies |
| Q36888218 | Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia |
| Q27853162 | Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. |
| Q27853190 | Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain |
| Q51123522 | Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. |
| Q58773255 | Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma |
| Q38644259 | Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity. |
| Q37731677 | Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma |
| Q90482750 | Advances in targeted therapy for malignant lymphoma |
| Q39227773 | Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia |
| Q34019917 | Advances in treating chronic lymphocytic leukemia |
| Q35978724 | An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases |
| Q57753502 | Analysis of Candidate Idarubicin Drug Resistance Genes in MOLT-3 Cells Using Exome Nuclear DNA |
| Q49592738 | Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets |
| Q61797222 | Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib |
| Q92401522 | Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib |
| Q49582344 | Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? |
| Q92839822 | Assessing Lysine and Cysteine Reactivities for Designing Targeted Covalent Kinase Inhibitors |
| Q38659428 | B-cell receptor pathway modulators in NHL. |
| Q35218042 | B-cell receptor signaling in diffuse large B-cell lymphoma |
| Q40469303 | BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia. |
| Q49546562 | BRD4 profiling identifies critical Chronic Lymphocytic Leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor |
| Q36799197 | BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia |
| Q38729031 | BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia |
| Q39227223 | Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia |
| Q89926249 | Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial |
| Q57821050 | Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia |
| Q38989496 | Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside |
| Q39006397 | Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia |
| Q38665207 | Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives |
| Q38351380 | Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas |
| Q50072188 | Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). |
| Q37687430 | CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma |
| Q27612411 | CIViC database |
| Q92890458 | CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition |
| Q58738700 | CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase |
| Q50430435 | Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics |
| Q38824435 | Cancer metabolism: a therapeutic perspective |
| Q36036102 | Cannabinoid Receptors Are Overexpressed in CLL but of Limited Potential for Therapeutic Exploitation |
| Q38766227 | Catalog of genetic progression of human cancers: non-Hodgkin lymphoma. |
| Q41848521 | Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia |
| Q34135450 | Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma |
| Q53377800 | Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches? |
| Q90330460 | Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived |
| Q26764833 | Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents |
| Q56270980 | Chronic lymphocytic leukaemia |
| Q39263974 | Chronic lymphocytic leukaemia genomics and the precision medicine era. |
| Q91666607 | Chronic lymphocytic leukaemia: from genetics to treatment |
| Q38675358 | Chronic lymphocytic leukemia (CLL)-Then and now. |
| Q60955786 | Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy |
| Q94562886 | Chronic lymphocytic leukemia in 2020: a surfeit of riches? |
| Q37113544 | Chronic lymphocytic leukemia therapy: new targeted therapies on the way |
| Q28082086 | Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment |
| Q38646074 | Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment |
| Q37710733 | Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia. |
| Q33774517 | Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib |
| Q49643911 | Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature. |
| Q38744632 | Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia |
| Q38962267 | Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation |
| Q90585781 | Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib |
| Q27027493 | Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond |
| Q27027942 | Clinical tumor sequencing: opportunities and challenges for precision cancer medicine |
| Q39406673 | Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms |
| Q49789839 | Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia |
| Q38262761 | Clonal evolution in chronic lymphocytic leukemia: impact of subclonality on disease progression |
| Q49557852 | Clonal evolution in leukemia |
| Q36925503 | Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition |
| Q40397638 | Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia |
| Q89776891 | Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL |
| Q58042774 | Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib |
| Q90710556 | Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications |
| Q42355443 | Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells |
| Q39933783 | Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. |
| Q38311898 | Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma. |
| Q46074725 | Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model. |
| Q91259857 | Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL |
| Q36900364 | Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens |
| Q28547976 | Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing |
| Q33442484 | Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia. |
| Q92887545 | Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL |
| Q29248430 | Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions |
| Q55447785 | Critical molecular pathways in CLL therapy. |
| Q39325783 | Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies |
| Q35852684 | Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells |
| Q40369611 | Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo |
| Q52684522 | Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase II study. |
| Q90871224 | Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment |
| Q38434264 | Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis |
| Q46244831 | Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3Kδ. |
| Q36240548 | Discovery of a Potent BTK Inhibitor with a Novel Binding Mode by Using Parallel Selections with a DNA-Encoded Chemical Library |
| Q36759124 | Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study |
| Q38919666 | Distinct and Overlapping Functions of TEC Kinase and BTK in B Cell Receptor Signaling |
| Q33851726 | Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. |
| Q39381251 | Drug discovery and therapeutic delivery for the treatment of B and T cell tumors. |
| Q37706530 | Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment |
| Q48618984 | Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib |
| Q39065374 | Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). |
| Q57752495 | Dynamic Allostery in PLCγ1 and Its Modulation by a Cancer Mutation Revealed by MD Simulation and NMR |
| Q41280348 | Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts |
| Q93223071 | Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma |
| Q36687288 | EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors |
| Q42701535 | EGFR T790M: revealing the secrets of a gatekeeper |
| Q47278073 | Effective management strategies for patients with marginal zone lymphoma |
| Q64113828 | Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models |
| Q39996013 | Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study |
| Q38543771 | Emerging immunological drugs for chronic lymphocytic leukemia |
| Q91994349 | Emerging treatment options for patients with p53-pathway-deficient CLL |
| Q93103183 | Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia |
| Q98733486 | Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry |
| Q48207016 | Enhancing the selectivity of kinase inhibitors in oncology: a chemical biology perspective. |
| Q34172063 | Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. |
| Q48338363 | Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue |
| Q35903984 | Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia |
| Q89004911 | Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials |
| Q54108755 | Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. |
| Q34280885 | Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL) |
| Q38764077 | Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting |
| Q47424531 | Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia |
| Q52645845 | First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. |
| Q38817591 | From identification of the BTK kinase to effective management of leukemia. |
| Q48307279 | Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia |
| Q38959765 | Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. |
| Q57821054 | Functional characterization of phospholipase C-γ mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder |
| Q39336821 | Genetic background and evolution of relapses in aggressive B-cell lymphomas. |
| Q38669131 | Genetic landscape and deregulated pathways in B-cell lymphoid malignancies |
| Q28087672 | Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia |
| Q51173647 | HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment. |
| Q40207115 | Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis |
| Q43083907 | Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer |
| Q39016282 | How I manage ibrutinib-refractory chronic lymphocytic leukemia |
| Q37587294 | How to unleash mitochondrial apoptotic blockades to kill cancers? |
| Q35820367 | Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation |
| Q34636880 | IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells |
| Q42578145 | Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy |
| Q47780043 | Ibrutinib and its use in the treatment of chronic lymphocytic leukemia |
| Q42091318 | Ibrutinib and rituximab induced rapid response in refractory Richter syndrome |
| Q36651344 | Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia |
| Q38694168 | Ibrutinib for mantle cell lymphoma |
| Q33419580 | Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial |
| Q38542260 | Ibrutinib for the treatment of Waldenström macroglobulinemia |
| Q38765015 | Ibrutinib for treatment of chronic lymphocytic leukemia |
| Q38545545 | Ibrutinib in B lymphoid malignancies |
| Q30252869 | Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib |
| Q35687553 | Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia |
| Q26783430 | Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion |
| Q90103630 | Ibrutinib in primary central nervous system diffuse large B-cell lymphoma |
| Q92823144 | Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial |
| Q35881570 | Ibrutinib resistance in chronic lymphocytic leukemia |
| Q90468316 | Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model |
| Q37688589 | Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia. |
| Q34352273 | Ibrutinib treatment of CLL: the cancer fights back |
| Q38524270 | Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target |
| Q38585329 | Ibrutinib-A double-edge sword in cancer and autoimmune disorders. |
| Q39010883 | Ibrutinib: A Review in Chronic Lymphocytic Leukaemia |
| Q26749010 | Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia |
| Q36739295 | Ibrutinib: a paradigm shift in management of CLL. |
| Q38388594 | Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia |
| Q38557067 | Ibrutinib: from bench side to clinical implications. |
| Q42315534 | Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. |
| Q28077136 | Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy |
| Q91855237 | Improving the Solubility, Dissolution, and Bioavailability of Ibrutinib by Preparing It in a Coamorphous State With Saccharin |
| Q38260343 | Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia. |
| Q101121282 | Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances |
| Q38691019 | Investigational Janus kinase inhibitors in development for myelofibrosis |
| Q38974011 | Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib |
| Q57287569 | Loss of TNFAIP3 enhances MYD88-driven signaling in non-Hodgkin lymphoma |
| Q38943877 | Magic pills: new oral drugs to treat chronic lymphocytic leukemia. |
| Q28081162 | Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors |
| Q50110556 | Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy. |
| Q34769213 | Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? |
| Q38725415 | Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib |
| Q39169789 | Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia |
| Q38413580 | Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma |
| Q38828353 | Mechanisms of tumor cell resistance to the current targeted-therapy agents. |
| Q38550810 | Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment |
| Q56514276 | Microenvironmental agonists generate phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL |
| Q90292627 | Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal? |
| Q90205302 | Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies |
| Q38424403 | Molecular deregulation of signaling in lymphoid tumors |
| Q92940374 | Molecular insight into the autoinhibition of a master regulator of lipid signalling in human disease |
| Q89082159 | Multiple myeloma clonal evolution in homogeneously treated patients |
| Q47786604 | NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib |
| Q89777249 | Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib |
| Q38646974 | New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia |
| Q91283875 | New roles for B cell receptor associated kinases: when the B cell is not the target |
| Q26828496 | New strategies in chronic lymphocytic leukemia: shifting treatment paradigms |
| Q88458406 | Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies |
| Q42378526 | Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons. |
| Q90407862 | Non-catalytic Bruton's tyrosine kinase activates PLCγ2 variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells |
| Q90292254 | Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL |
| Q92884419 | Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity |
| Q89477099 | Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia |
| Q38516704 | Novel agents in mantle cell lymphoma |
| Q39290199 | Novel agents in mantle cell lymphoma |
| Q27304386 | Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review |
| Q47932240 | Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia |
| Q38308974 | Novel therapeutic options for relapsed hairy cell leukemia |
| Q36065294 | Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia. |
| Q91697992 | Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study |
| Q40532403 | Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. |
| Q38978727 | Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. |
| Q41137752 | Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients |
| Q35812675 | Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia |
| Q35563832 | Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure |
| Q41601558 | Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib |
| Q36685547 | PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia. |
| Q26782633 | PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL) |
| Q33785941 | PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis |
| Q36274292 | PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors |
| Q34106863 | PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL. |
| Q53745405 | PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment. |
| Q89014299 | PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies |
| Q92310282 | PROTACs: great opportunities for academia and industry |
| Q92758119 | PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future |
| Q38364911 | Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. |
| Q38851368 | Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future? |
| Q53963822 | Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. |
| Q35958056 | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia |
| Q38818283 | Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. |
| Q64230024 | Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma |
| Q88957428 | Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia |
| Q33420278 | Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma |
| Q38397004 | Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. |
| Q38984735 | Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies |
| Q88886221 | Pitfalls of Combining Novel Agents in Lymphoma |
| Q90270152 | Precision Medicine Management of Chronic Lymphocytic Leukemia |
| Q36288987 | Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials |
| Q41865162 | Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia |
| Q45050435 | Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study |
| Q35895622 | Preventing clonal evolutionary processes in cancer: Insights from mathematical models |
| Q38755091 | Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia |
| Q39145934 | Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia |
| Q30240258 | Prognostication of chronic lymphocytic leukemia in the era of new agents |
| Q39433250 | Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors |
| Q52812536 | Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward? |
| Q30248407 | Reappraising the timing of transplant for indolent non-Hodgkin lymphomas |
| Q46318389 | Recent therapeutic advances in chronic lymphocytic leukemia |
| Q37609908 | Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. |
| Q92430952 | Repurposing dasatinib for diffuse large B cell lymphoma |
| Q64230239 | Resistance mechanism for ibrutinib in marginal zone lymphoma |
| Q91698051 | Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies |
| Q97524840 | Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents |
| Q53691981 | Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines. |
| Q89562799 | Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm |
| Q90029192 | Richter transformation in the era of novel agents |
| Q47882529 | Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation |
| Q49888075 | Role of Bruton's tyrosine kinase in B cells and malignancies |
| Q26795594 | Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms |
| Q39472422 | Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies |
| Q28076118 | Second-generation inhibitors of Bruton tyrosine kinase |
| Q28087213 | Secondary mutations as mediators of resistance to targeted therapy in leukemia |
| Q35607285 | Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia |
| Q30240243 | Sequencing of chronic lymphocytic leukemia therapies. |
| Q90451364 | Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias |
| Q47709959 | Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. |
| Q38691282 | Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma. |
| Q102075600 | Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes |
| Q36161658 | Specificity and biologic activities of novel anti-membrane IgM antibodies |
| Q37742056 | Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia |
| Q92337963 | Structural basis for the activation of PLC-γ isozymes by phosphorylation and cancer-associated mutations |
| Q92521555 | Structural insights and activating mutations in diverse pathologies define mechanisms of deregulation for phospholipase C gamma enzymes |
| Q64095477 | Structural mechanism for Bruton's tyrosine kinase activation at the cell membrane |
| Q38765458 | Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant. |
| Q94671635 | Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies |
| Q36091288 | Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib |
| Q50078371 | TNF receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin |
| Q59797087 | TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics |
| Q35775881 | Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors |
| Q90693846 | Targeted Therapies: Friends or Foes for Patient's NK Cell-Mediated Tumor Immune-Surveillance? |
| Q41230395 | Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells |
| Q90215897 | Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation |
| Q39560208 | Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. |
| Q27002528 | Targeted therapies in CLL: mechanisms of resistance and strategies for management |
| Q54344316 | Targeted therapies: ibrutinib resonates with us. |
| Q38331701 | Targeted therapy for chronic lymphocytic leukemia: current status and future directions |
| Q38738661 | Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future |
| Q38654101 | Targeting B Cell Signaling in Chronic Lymphocytic Leukemia |
| Q49951221 | Targeting B cell receptor signalling in cancer: preclinical and clinical advances |
| Q92158076 | Targeting B-cell receptor signaling in leukemia and lymphoma: how and why? |
| Q26744277 | Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib |
| Q34504188 | Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia |
| Q35979385 | Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia. |
| Q48967836 | Targeting BTK through microRNA in chronic lymphocytic leukemia |
| Q58613953 | Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies |
| Q38351184 | Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies |
| Q36544683 | Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia. |
| Q26865765 | Targeting cancer with kinase inhibitors |
| Q38862584 | Targeting neddylation effectively antagonizes nuclear factor-κB in chronic lymphocytic leukemia B-cells |
| Q38744922 | Targeting of B-cell receptor signalling in B-cell malignancies. |
| Q55015828 | Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. |
| Q54977449 | Targeting the B cell receptor pathway in non-Hodgkin lymphoma. |
| Q46566477 | The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia |
| Q35583403 | The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. |
| Q43090573 | The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia |
| Q28830861 | The European Hematology Association Roadmap for European Hematology Research: a consensus document |
| Q42383180 | The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein |
| Q47796704 | The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars |
| Q57752422 | The Src module: an ancient scaffold in the evolution of cytoplasmic tyrosine kinases |
| Q28075683 | The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia |
| Q26749214 | The clinical implications of gene mutations in chronic lymphocytic leukaemia |
| Q38584629 | The clinical safety of ibrutinib in chronic lymphocytic leukemia |
| Q47102996 | The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. |
| Q38286344 | The genomic landscape of chronic lymphocytic leukaemia: biological and clinical implications |
| Q90569013 | The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia |
| Q26781693 | The influence of subclonal resistance mutations on targeted cancer therapy |
| Q35814547 | The ins and outs of selective kinase inhibitor development |
| Q39061630 | The landscape of new drugs in lymphoma |
| Q47804413 | The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma |
| Q38748645 | The molecular pathogenesis of chronic lymphocytic leukaemia |
| Q101564368 | The nuclear export protein XPO1 - from biology to targeted therapy |
| Q40575812 | The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells. |
| Q51014811 | The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia. |
| Q28075504 | The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia |
| Q44633375 | The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax. |
| Q39039006 | The recurrent architecture of tumour initiation, progression and drug sensitivity |
| Q26775506 | The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia |
| Q38728631 | The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy |
| Q38638852 | The role of phospholipase Cγ1 in breast cancer and its clinical significance |
| Q38719429 | The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia |
| Q30243968 | The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia |
| Q42368337 | The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies |
| Q41708887 | The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells. |
| Q36998859 | Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice |
| Q35450520 | Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib |
| Q34625543 | Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies? |
| Q41189462 | Treating EGFR mutation resistance in non-small cell lung cancer - role of osimertinib |
| Q34892977 | Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest |
| Q94957224 | UGT2B17 modifies drug response in chronic lymphocytic leukaemia |
| Q37633475 | Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial |
| Q90593423 | Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study |
| Q53237596 | Understanding cancer cell survival is key to patient survival. |
| Q92627012 | Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months |
| Q33587128 | Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma |
| Q90331382 | Unmask the genetic backbone of ibrutinib-relapsed chronic lymphocytic leukemia progression and Richter transformation |
| Q33566747 | Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors |
| Q38523991 | VIII. Treatment of chronic lymphocytic leukaemia, where are we heading? |
| Q52759227 | Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors. |
| Q47300370 | Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial |
| Q41070355 | Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. |
| Q98458131 | ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer |
| Q54309968 | [Chronic lymphocytic leukemia: current standards and novel approaches]. |
| Q89454901 | [Clinical study and application of Ibrutinib in B-cell non-Hodgkin's lymphomas] |
| Q39694093 | p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL. |
Search more.